KYMR as reported
Kymera Therapeutics, Inc. reported $105M of revenue over the trailing twelve months, +135% on the year before. 9 reported series are charted on this page, each one as filed.
$105M
Revenue, trailing twelve months · to Q2 2026 · +135% against the twelve months before
- Net Income
- −$300M
Net Income · +8.8% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$238M
Free Cash Flow · −6.1% year on year · trailing twelve months to Q2 2026
- Op Margin
- −1780%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $105M | +135% | Q2 2026 |
| Net Income | −$300M | +8.8% | Q2 2026 |
| EPS | −$3.25 | −6.6% | Q2 2026 |
| Gross Margin | 0.00% | n/a | Q2 2026 |
| Op Margin | −1780% | n/a | Q2 2026 |
| Net Margin | −1575% | n/a | Q2 2026 |
| ROE | −23% | n/a | Q2 2026 |
| ROA | −20% | n/a | Q2 2026 |
| Free Cash Flow | −$238M | −6.1% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Kymera Therapeutics, Inc. (KYMR) - Revenue & ProfitRevenue & ProfitKymera Therapeutics, Inc. (KYMR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com